## Geertjan van Tienhoven

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3600501/publications.pdf

Version: 2024-02-01

66343 28297 11,791 117 42 105 citations h-index g-index papers 117 117 117 11157 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC) Tj ETQq1 1 0.784314 Oncology, The, 2014, 15, 1303-1310.	rgBT /Over 10.7	erlock 10 T <mark>f 5</mark> 1,356
2	Duration of Androgen Suppression in the Treatment of Prostate Cancer. New England Journal of Medicine, 2009, 360, 2516-2527.	27.0	865
3	Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. New England Journal of Medicine, 2015, 373, 317-327.	27.0	847
4	External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncology, The, 2010, 11, 1066-1073.	10.7	830
5	Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet, The, 2012, 380, 2018-2027.	13.7	759
6	Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. Journal of Clinical Oncology, 2020, 38, 1763-1773.	1.6	665
7	The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiotherapy and Oncology, 1999, 52, 101-109.	0.6	607
8	The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy. Journal of Clinical Oncology, 2005, 23, 2130-2135.	1.6	564
9	Differences in Risk Factors for Local and Distant Recurrence After Breast-Conserving Therapy or Mastectomy for Stage I and II Breast Cancer: Pooled Results of Two Large European Randomized Trials. Journal of Clinical Oncology, 2001, 19, 1688-1697.	1.6	504
10	Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 199-207.	8.1	393
11	Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. Journal of Clinical Oncology, 2022, 40, 1220-1230.	1.6	274
12	Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study. Journal of Clinical Oncology, 2010, 28, 4450-4456.	1.6	254
13	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Journal of the National Cancer Institute, 2019, 111, 782-794.	6.3	223
14	Sentinel Node Identification Rate and Nodal Involvement in the EORTC 10981-22023 AMAROS Trial. Annals of Surgical Oncology, 2010, 17, 1854-1861.	1.5	202
15	Internal mammary and medial supraclavicular lymph node chain irradiation in stage l–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncology, The, 2020, 21, 1602-1610.	10.7	164
16	Role of Axillary Clearance After a Tumor-Positive Sentinel Node in the Administration of Adjuvant Therapy in Early Breast Cancer. Journal of Clinical Oncology, 2010, 28, 731-737.	1.6	163
17	Local recurrence after breast conservation therapy for early stage breast carcinoma. , 1999, 85, 437-446.		143
18	Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. Trials, 2016, 17, 127.	1.6	131

#	Article	IF	Citations
19	Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial Journal of Clinical Oncology, 2018, 36, LBA4002-LBA4002.	1.6	120
20	Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer, 2000, 89, 2222-2229.	4.1	108
21	Adaptive radiotherapy for invasive bladder cancer: A feasibility study. International Journal of Radiation Oncology Biology Physics, 2006, 64, 862-868.	0.8	103
22	Nationwide trends in incidence, treatmentÂand survival of pancreatic ductal adenocarcinoma. European Journal of Cancer, 2020, 125, 83-93.	2.8	98
23	Influence of bladder and rectal volume on spatial variability of a bladder tumor during radical radiotherapy. International Journal of Radiation Oncology Biology Physics, 2003, 55, 835-841.	0.8	92
24	Neoadjuvant therapy or upfront surgery for resectableÂand borderline resectable pancreatic cancer: AÂmeta-analysis of randomised controlled trials. European Journal of Cancer, 2022, 160, 140-149.	2.8	90
25	The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC Phase III randomized trial 22922/10925 in Stage l–III breast cancer. International Journal of Radiation Oncology Biology Physics, 2001. 49, 1399-1408.	0.8	85
26	Efficacy of radiotherapy for painful bone metastases during the last 12 weeks of life. Cancer, 2010, 116, 2716-2725.	4.1	77
27	Temperature and thermal dose during radiotherapy and hyperthermia for recurrent breast cancer are related to clinical outcome and thermal toxicity: a systematic review. International Journal of Hyperthermia, 2019, 36, 1023-1038.	2.5	72
28	Interfractional Position Variation of Pancreatic Tumors Quantified Using Intratumoral Fiducial Markers and Daily Cone Beam Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2013, 87, 202-208.	0.8	71
29	Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run. Radiotherapy and Oncology, 2003, 68, 233-240.	0.6	69
30	Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023) Journal of Clinical Oncology, 2013, 31, LBA1001-LBA1001.	1.6	69
31	Concomitant boost radiotherapy for muscle invasive bladder cancer. Radiotherapy and Oncology, 2003, 68, 75-80.	0.6	63
32	Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. Cancers, 2019, 11, 976.	3.7	63
33	Reirradiation and hyperthermia for irresectable locoregional recurrent breast cancer in previously irradiated area: Size matters. Radiotherapy and Oncology, 2015, 117, 223-228.	0.6	60
34	Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). European Journal of Cancer, 2014, 50, 2983-2993.	2.8	56
35	Differences in respiratory-induced pancreatic tumor motion between 4D treatment planning CT and daily cone beam CT, measured using intratumoral fiducials. Acta Oncológica, 2014, 53, 1257-1264.	1.8	55
36	Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3â€98. Psycho-Oncology, 2014, 23, 173-182.	2.3	55

#	Article	IF	CITATIONS
37	Probiotics for the preventionÂor treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer. The Cochrane Library, 2018, 2018, CD008831.	2.8	54
38	All eyes on the patient: the influence of oncologists' nonverbal communication on breast cancer patients' trust. Breast Cancer Research and Treatment, 2015, 153, 161-171.	2.5	53
39	Reirradiation and hyperthermia for radiationâ€associated sarcoma. Cancer, 2012, 118, 180-187.	4.1	44
40	Visibility and artifacts of gold fiducial markers used for image guided radiation therapy of pancreatic cancer on MRI. Medical Physics, 2015, 42, 2638-2647.	3.0	44
41	Feasibility and repeatability of PET with the hypoxia tracer [18F]HX4 in oesophageal and pancreatic cancer. Radiotherapy and Oncology, 2015, 116, 94-99.	0.6	44
42	Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. European Journal of Cancer, 2004, 40, 1674-1681.	2.8	43
43	Establishing and Coordinating a Nationwide Multidisciplinary Study Group: Lessons Learned by the Dutch Pancreatic Cancer Group. Annals of Surgery, 2020, 271, e102-e104.	4.2	43
44	The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. International Journal of Hyperthermia, 2018, 34, 969-979.	2.5	41
45	Elective re-irradiation and hyperthermia following resection of persistent locoregional recurrent breast cancer: A retrospective study. International Journal of Hyperthermia, 2010, 26, 136-144.	2.5	39
46	Comparison of the sentinel node procedure between patients with multifocal and unifocal breast cancer in the EORTC 10981-22023 AMAROS Trial: Identification rate and nodal outcome. European Journal of Cancer, 2013, 49, 2093-2100.	2.8	37
47	Abdominal organ motion during inhalation and exhalation breath-holds: pancreatic motion at different lung volumes compared. Radiotherapy and Oncology, 2016, 121, 268-275.	0.6	37
48	Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. European Journal of Cancer, 2020, 125, 69-82.	2.8	36
49	Quality Assurance in the EORTC Randomized Trial 22922/10925 Investigating the Role of Irradiation of the Internal Mammary and Medial Supraclavicular Lymph Node Chain Works. Strahlentherapie Und Onkologie, 2006, 182, 576-582.	2.0	35
50	Considerable pancreatic tumor motion during breath-holding. Acta Oncológica, 2016, 55, 1360-1368.	1.8	32
51	Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Modern Pathology, 2021, 34, 4-12.	<b>5.</b> 5	32
52	Highâ€grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSFâ€1. EMBO Reports, 2020, 21, e48780.	<b>4.</b> 5	29
53	Primary radiotherapy of breast cancer: Treatment results in locally advanced breast cancer and in operable patients selected by positive axillary apex biopsy. Radiotherapy and Oncology, 1992, 25, 1-11.	0.6	28
54	Limited Role for Biliary Stent as Surrogate Fiducial Marker in Pancreatic Cancer: Stent and Intratumoral Fiducials Compared. International Journal of Radiation Oncology Biology Physics, 2014, 89, 641-648.	0.8	26

#	Article	IF	Citations
55	Pain management of patients with unresectable peripancreatic carcinoma. World Journal of Surgery, 2002, 26, 715-720.	1.6	25
56	Thermal Skin Damage During Reirradiation and Hyperthermia Is Time-Temperature Dependent. International Journal of Radiation Oncology Biology Physics, 2017, 98, 392-399.	0.8	25
57	Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (10981/22023) Journal of Clinical Oncology, 2013, 31, LBA1001-LBA1001.	1.6	25
58	Estrogen Receptor Status in Primary Breast Cancer: Iodine 123–labeledcis-11β-Methoxy-17α-iodovinyl Estradiol Scintigraphy. Radiology, 2001, 220, 774-779.	7.3	24
59	Pain relief after a short course of palliative radiotherapy in pancreatic cancer, the Academic Medical Center (AMC) experience. Acta Oncol $ ilde{A}^3$ gica, 2018, 57, 697-700.	1.8	24
60	Quality assurance in the EORTC phase III randomised †boost vs. no boost' trial for breast conserving therapy: Comparison of the results of two individual case reviews performed early and late during the accrual period. Radiotherapy and Oncology, 2005, 76, 278-284.	0.6	23
61	Non-surgical interventions for late rectal problems (proctopathy) of radiotherapy in people who have received radiotherapy to the pelvis. The Cochrane Library, 2016, 4, CD003455.	2.8	23
62	Addition of MRI for CT-based pancreatic tumor delineation: a feasibility study. Acta Oncol $\tilde{A}^3$ gica, 2017, 56, 923-930.	1.8	23
63	ReirradiationÂ+ hyperthermia for recurrent breast cancer en cuirasse. Strahlentherapie Und Onkologie, 2018, 194, 206-214.	2.0	23
64	Pathological validation and prognostic potential of quantitative MRI in the characterization of pancreas cancer: preliminary experience. Molecular Oncology, 2020, 14, 2176-2189.	4.6	23
65	Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: A multicentre retrospective cohort study. European Journal of Surgical Oncology, 2021, 47, 2525-2532.	1.0	21
66	Predictors of enduring clinical distress in women with breast cancer. Breast Cancer Research and Treatment, 2016, 158, 563-572.	2.5	20
67	Evaluation of Six Diffusion-weighted MRI Models for Assessing Effects of Neoadjuvant Chemoradiation in Pancreatic Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1052-1062.	0.8	20
68	Risk factors of unmet needs among women with breast cancer in the postâ€treatment phase. Psycho-Oncology, 2020, 29, 539-549.	2.3	20
69	Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma. Therapeutic Advances in Medical Oncology, 2011, 3, 27-33.	3.2	19
70	Dosimetric Advantages of Midventilation Compared With Internal Target Volume for Radiation Therapy of Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 675-682.	0.8	19
71	Oncologists' non-verbal behavior and analog patients' recall of information. Acta Oncológica, 2016, 55, 671-679.	1.8	19
72	Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2021, 28, 8297-8308.	1.5	19

#	Article	IF	Citations
73	Postmastectomy Radiotherapy: Will the Selective Use of Postmastectomy Radiotherapy Study End the Debate?. Journal of Clinical Oncology, 2009, 27, 996-997.	1.6	18
74	Considerable interobserver variation in delineation of pancreatic cancer on 3DCT and 4DCT: a multi-institutional study. Radiation Oncology, 2017, 12, 58.	2.7	17
75	Office hours pulsed brachytherapy boost in breast cancer. Radiotherapy and Oncology, 2001, 59, 273-280.	0.6	16
76	Quality assurance in the EORTC 22921 trial on preoperative radiotherapy with or without chemotherapy for resectable rectal cancer. European Journal of Cancer, 2002, 38, 1849-1856.	2.8	16
77	Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. Radiotherapy and Oncology, 2011, 98, 261-264.	0.6	16
78	Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life. Supportive Care in Cancer, 2016, 24, 1617-1623.	2.2	16
79	Analysis of clinical data to determine the minimum number of sensors required for adequate skin temperature monitoring of superficial hyperthermia treatments. International Journal of Hyperthermia, 2018, 34, 910-917.	2.5	15
80	Dosimetric effects of anatomical changes during fractionated photon radiation therapy in pancreatic cancer patients. Journal of Applied Clinical Medical Physics, 2017, 18, 142-151.	1.9	14
81	Locoregional peritoneal hyperthermia to enhance the effectiveness of chemotherapy in patients with peritoneal carcinomatosis: a simulation study comparing different locoregional heating systems. International Journal of Hyperthermia, 2020, 37, 76-88.	2.5	14
82	Rib fractures after reirradiation plus hyperthermia for recurrent breast cancer. Strahlentherapie Und Onkologie, 2016, 192, 240-247.	2.0	13
83	Conservative local treatment versus mastectomy after induction chemotherapy in locally advanced breast cancer: A randomised phase III study (EORTC 10974/22002, LAMANOMA) – Why did this study fail?. European Journal of Cancer, 2005, 41, 2787-2788.	2.8	12
84	Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. Clinical Cancer Research, 2015, 21, 4569-4575.	7.0	12
85	Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data. Frontiers in Oncology, 2020, 10, 1112.	2.8	12
86	Fifteen-year results of the randomised EORTC trial 22922/10925 investigating internal mammary and medial supraclavicular (IM-MS) lymph node irradiation in stage I-III breast cancer Journal of Clinical Oncology, 2018, 36, 504-504.	1.6	11
87	Post-operative re-irradiation with hyperthermia in locoregional breast cancer recurrence: Temperature matters. Radiotherapy and Oncology, 2022, 167, 149-157.	0.6	11
88	Local and Systemic Outcomes in DCIS Based on Tumor and Patient Characteristics: The Radiation Oncologist's Perspective. Journal of the National Cancer Institute Monographs, 2010, 2010, 178-180.	2.1	10
89	Soluble Compounds Released by Hypoxic Stroma Confer Invasive Properties to Pancreatic Ductal Adenocarcinoma. Biomedicines, 2020, 8, 444.	3.2	9
90	Clinical Feasibility of a High-Resolution Thermal Monitoring Sheet for Superficial Hyperthermia in Breast Cancer Patients. Cancers, 2020, 12, 3644.	3.7	8

#	Article	IF	CITATIONS
91	Two high-resolution thermal monitoring sheets for clinical superficial hyperthermia. Physics in Medicine and Biology, 2020, 65, 175021.	3.0	8
92	Position Verification for the Prostate: Effect on Rectal Wall Dose. International Journal of Radiation Oncology Biology Physics, 2011, 80, 462-468.	0.8	7
93	Quantitative assessment of biliary stent artifacts on MR images: Potential implications for target delineation in radiotherapy. Medical Physics, 2016, 43, 5603-5615.	3.0	7
94	A flexible 70 MHz phase-controlled double waveguide system for hyperthermia treatment of superficial tumours with deep infiltration. International Journal of Hyperthermia, 2017, 33, 1-14.	2.5	7
95	Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer. Strahlentherapie Und Onkologie, 2017, 193, 630-638.	2.0	7
96	Don't forget the dentist: Dental care use and needs of women with breast cancer. Breast, 2016, 29, 1-7.	2.2	6
97	Evaluating differences in respiratory motion estimates during radiotherapy: a single planning 4DMRI versus daily 4DMRI. Radiation Oncology, 2021, 16, 188.	2.7	6
98	Erratum to " The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study―[Radiother. Oncol. 52 (1999) 101–109]. Radiotherapy and Oncology, 1999, 53, 167.	0.6	5
99	Adaptive margin radiotherapy for patients with prostate carcinoma: What's the benefit?. Radiotherapy and Oncology, 2012, 105, 203-206.	0.6	5
100	Probabilistic treatment planning for pancreatic cancer treatment: prospective incorporation of respiratory motion shows only limited dosimetric benefit. Acta Oncol³gica, 2017, 56, 398-404.	1.8	5
101	Health care use and remaining needs for support among women with breast cancer in the first 15 months after diagnosis: the role of the GP. Family Practice, 2020, 37, 103-109.	1.9	5
102	Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?. Frontiers in Oncology, 2021, 11, 744161.	2.8	5
103	The EORTC Breast Cancer Group: major achievements of 50 years of research and future directions. European Journal of Cancer, Supplement, 2012, 10, 27-33.	2.2	4
104	Radiotherapy or surgery for the axilla in node-positive breast cancer? – Authors' reply. Lancet Oncology, The, 2015, 16, e54.	10.7	4
105	The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy. European Journal of Cancer, 2021, 155, 28-37.	2.8	4
106	External Validity of the Multicenter Randomized PREOPANC Trial on Neoadjuvant Chemoradiotherapy in Pancreatic Cancer. Annals of Surgery, 2020, Publish Ahead of Print, .	4.2	4
107	A randomized phase-II study of reirradiation and hyperthermia versus reirradiation and hyperthermia plus chemotherapy for locally recurrent breast cancer in previously irradiated area. Acta Oncol $\tilde{A}^3$ gica, 2022, 61, 441-448.	1.8	4
108	Probiotics for the preventionÂor treatment of chemotherapy or radiotherapy relatedÂdiarrhoeaÂin cancer patients. The Cochrane Library, 2013, , .	2.8	3

#	Article	IF	CITATIONS
109	Development of a 70 MHz unit for hyperthermia treatment of deep-seated breast tumors. International Journal of Microwave and Wireless Technologies, 2017, 9, 1317-1324.	1.9	3
110	Defining short and prolonged breath-holds. British Journal of Radiology, 2020, 93, 20200191.	2.2	3
111	Postmastectomy radiotherapy should not be standard of care for women with 1–3 involved nodes. Radiotherapy and Oncology, 2007, 84, 103-104.	0.6	2
112	Reply to S. Shi et al and G.W. Peters et al. Journal of Clinical Oncology, 2020, 38, 2945-2946.	1.6	2
113	Breast Cancer: Disentangling the Intricate Web. Journal of Clinical Oncology, 2010, 28, e281-e281.	1.6	1
114	ASO Visual Abstract: Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer—A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2021, 28, 485-487.	1.5	1
115	Reply to W. Attaallah, A. Jain et al, and P. Mroczkowski et al. Journal of Clinical Oncology, 0, , .	1.6	1
116	Prognosis of patients with locally recurrent breast cancer. American Journal of Surgery, 2007, 193, 138.	1.8	0
117	Occurrence of seeding metastases in resectable perihilar cholangiocarcinoma and the role of low-dose radiotherapy to prevent this. World Journal of Hepatology, 2020, 12, 1089-1097.	2.0	O